FDA-filed SPL labeling · retrieved through openFDA

Octreotide

Octreotide is a synthetic hormone-like medicine used to treat acromegaly (a condition of excess growth hormone) and to control severe diarrhea and flushing caused by certain hormone-secreting tumors.

Brand names MycapssaSandostatinBynfeziaSandostatin LAR DepotBYNFEZIA Pen
Rx Forms 2 Routes Intravenous; Subcutaneous · Intravenous, Subcutaneous · Oral · Intramuscular +2
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 14 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

At a glance
Linked label effectiveJul 30, 2024
Clinical labels in scope ⓘ14
AvailabilityRx
Earliest approval/marketing year ⓘ1988
FDA-listed product records ⓘ133
Boxed warningNone found in compared labels
How we combine label and product data →
✓No current FDA shortage listed · checked Sep 22, 2026 🚨Recall on record · 4
Other forms & routes:
Injection
⭐ Octreotide at a glance The quick version — the full detail is in the Patient Information Guide below.
💊
HelloPharmacist Editorial Team Bottom Line
Octreotide is a potent hormone-regulating medicine used to treat acromegaly and to control serious symptoms from hormone-secreting tumors like carcinoid tumors and VIPomas. It requires regular monitoring — especially for gallstones, blood sugar changes, thyroid function, and heart rhythm. Take it exactly as prescribed, and keep all follow-up appointments so your care team can watch for these known risks.
How we write & review this content — our editorial policy →

📖 Octreotide: Patient Information Guide

A plain-language walkthrough of Octreotide — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.

🎯What it's used for▾

Octreotide is a somatostatin analogue (a synthetic copy of a natural hormone) approved across several products and formulations for the following conditions:

  • Acromegaly — All octreotide injection products (Sandostatin, BYNFEZIA Pen, and octreotide acetate injections) are approved to lower growth hormone (GH) and IGF-1 levels in patients who have not responded adequately to surgery, radiation, or bromocriptine. Mycapssa (oral capsule) is approved specifically for long-term maintenance in acromegaly patients who have already responded to and tolerated octreotide or lanreotide injections.
  • Metastatic carcinoid tumors — Octreotide acetate injections and Sandostatin injection are approved to reduce the severe diarrhea and flushing episodes these tumors cause. Note: clinical trials with injection formulations did not demonstrate shrinkage of tumors or slowing of tumor growth.
  • VIPomas (vasoactive intestinal peptide-secreting tumors) — Octreotide acetate injections, BYNFEZIA Pen, and Sandostatin injection are approved for the profuse watery diarrhea caused by these tumors. The same limitation regarding tumor size and growth applies.
⚙️How it works▾

Octreotide works by mimicking somatostatin, a hormone your body naturally produces to put the brakes on other hormones. It is a far more potent version of somatostatin — blocking the release of growth hormone, glucagon, insulin, serotonin, VIP, and several other gut hormones. In acromegaly, this brings dangerously high growth hormone levels down. In carcinoid tumors and VIPomas, it quiets the flood of hormones those tumors release, which is what causes the debilitating diarrhea and flushing episodes.

💊How it's taken▾

Octreotide is available as injections (given under the skin or into a vein) and as Mycapssa, an oral delayed-release capsule. Injection products are typically given multiple times per day; injection sites should be rotated regularly to avoid irritation. Mycapssa is taken by mouth twice daily on a completely empty stomach — food reduces absorption by roughly 90%, so timing really matters. Your prescriber will adjust your dose based on your hormone levels and symptoms over time. Always follow your personalized prescription instructions.

🤒Side effects — in detail▾

The most common side effects of octreotide include:

  • Diarrhea and loose stools
  • Abdominal pain or cramping
  • Nausea and vomiting
  • Gas and bloating
  • Headache
  • Dizziness and fatigue
  • Injection site pain (with injectable forms)
  • Constipation

More serious reactions — including gallstone complications, heart rhythm changes, significant blood sugar swings, and hypothyroidism — require prompt medical attention. Contact your doctor right away if you develop severe stomach pain, yellowing of the skin, a very slow or irregular heartbeat, or signs of dangerously low blood sugar.

⚠️Warnings & precautions▾
  • Gallstones and gallbladder problems: Octreotide slows gallbladder emptying, and over half of long-term users develop some gallbladder abnormality. Serious complications like acute cholecystitis, bile duct blockage, or pancreatitis can occur and may require stopping treatment.
  • Heart rhythm problems: Octreotide can slow the heart rate, cause conduction abnormalities, and — especially when given intravenously at high doses — has been linked to complete heart block. Cardiac monitoring is recommended for IV use.
  • Blood sugar changes: By altering the balance of insulin and glucagon, octreotide can cause both low blood sugar (hypoglycemia) and high blood sugar (hyperglycemia). Diabetic patients need especially close monitoring.
  • Hypothyroidism: Octreotide suppresses the thyroid-stimulating hormone and can cause an underactive thyroid over time. Thyroid function should be checked periodically during long-term use.
  • Fat malabsorption: Octreotide can reduce pancreatic enzyme output, leading to greasy stools, bloating, and weight loss. Report these symptoms to your doctor.
  • Vitamin B12: Some patients develop lower vitamin B12 levels during treatment; periodic monitoring is recommended.
🔀What it interacts with▾

Octreotide can interact with a number of medications — tell your doctor and pharmacist everything you take:

  • Antacids, PPIs, and H2-blockers (e.g., omeprazole, famotidine): reduce Mycapssa absorption — a higher dose of Mycapssa may be needed
  • Insulin and diabetes medicines: octreotide changes blood sugar balance, so doses of these drugs may need adjustment
  • Cyclosporine: Mycapssa can lower cyclosporine levels, possibly reducing its effectiveness
  • Digoxin: Mycapssa may reduce digoxin levels — careful monitoring needed given digoxin's narrow safety margin
  • Lisinopril: Mycapssa may increase lisinopril levels, raising the risk of low blood pressure
  • Hormonal birth control containing levonorgestrel: Mycapssa may reduce its effectiveness — use a backup contraceptive method
  • Bromocriptine: octreotide may increase bromocriptine exposure — dose adjustment may be needed
  • Beta-blockers and calcium channel blockers: octreotide's heart-rate-slowing effect can compound theirs — dose adjustments may be needed
  • CYP3A4-metabolized drugs with a narrow safety window (e.g., quinidine): octreotide may increase their levels — use with extra caution and monitoring

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

📋Before taking it▾
  • Allergy to octreotide: Do not take if you have had a severe allergic reaction (including anaphylaxis) to octreotide or any component of the product
  • Heart problems: Tell your doctor if you have a slow heart rate, heart rhythm disorder, or heart failure — octreotide can worsen these
  • Gallbladder disease: Tell your doctor about any history of gallstones — your risk of new or worsening gallbladder problems is increased
  • Diabetes or blood sugar disorders: Glucose monitoring is essential; your diabetes medicines may need dose changes
  • Thyroid disease: Octreotide can suppress thyroid function — baseline and periodic thyroid tests are recommended
  • Kidney failure requiring dialysis: Drug exposure is higher — lower starting doses are recommended
  • Liver cirrhosis: Drug is cleared more slowly — lower starting doses are recommended
  • Pregnancy: Data are limited; discuss risks with your doctor. Women with acromegaly should know that normalizing IGF-1 may improve fertility — use effective contraception if pregnancy is not desired
  • Breastfeeding: It is not known whether octreotide passes into human breast milk — weigh the benefits and risks with your doctor
  • Children: Safety and efficacy of injectable suspension have not been established in children under 6; serious adverse events including death have been reported in children under 2 with octreotide acetate injection
  • Older adults: The drug is cleared more slowly in people 65 and older — careful, cautious dosing is recommended
🚑If you take too much▾

Too much octreotide can cause serious heart problems (including arrhythmia and complete heart block), very low blood pressure, pancreatitis, liver inflammation, lactic acidosis, diarrhea, flushing, and extreme fatigue. If you suspect an overdose, treatment is focused on managing symptoms. Contact the National Poison Control Center at 1-800-222-1222 or seek emergency medical care immediately.

📡Pharmacodynamics — effects in the body▾

Octreotide measurably lowers growth hormone and IGF-1 levels in patients with acromegaly and can normalize them in many cases. It also reduces gallbladder contractions and bile flow, which is why gallstone formation is a known risk with long-term use. Octreotide can meaningfully suppress TSH (thyroid-stimulating hormone), potentially causing an underactive thyroid. When taken as Mycapssa, it temporarily increases intestinal permeability to allow absorption — an effect that is fully reversed within about 5.5 hours.

🔬Pharmacokinetics — how your body processes it▾

When injected subcutaneously, octreotide is absorbed rapidly, reaching peak blood levels within about 0.4 hours. It is about 65% bound to proteins in the blood, primarily lipoproteins. The drug has a short elimination half-life of roughly 1.7–2.7 hours after injection, though it acts longer than that in practice. About 32% is excreted unchanged in the urine. Elimination is significantly slower in people with liver cirrhosis or severe kidney failure requiring dialysis, and also slows with age — all of which can mean higher drug exposure and a need for lower doses. Mycapssa, the oral form, must be taken on an empty stomach because food reduces its absorption by about 90%.

📦How to store it▾

Store refrigerated between 2° and 8°C (36° and 46°F). Protect from light.

📄 Written from Octreotide’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →

30

Supplements & herbs that interact with Octreotide

30 supplements and herbal products have documented interactions with Octreotide in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 1
  • Moderate · 19
  • Minor · 10
ACTIVATED CHARCOAL Major ADRAFINIL Moderate CANNABIDIOL (CBD) Moderate CANNABINOL (CBN) Moderate CANNABIS Moderate COFFEE CHARCOAL Moderate DELTA-9-TETRAHYDROCANNABINOL (THC) Moderate ERGOT Moderate +22 more
Every supplement checked against Octreotide — ranked by severity The full interaction hub: 1 major · 19 moderate · 10 minor · every one linked to its full report. Check Octreotide against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

🩺 Pharmacist Counseling Corner

Quick, plain-English answers to the questions patients ask most about Octreotide — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly does octreotide do — and why do I need it? ▾
Octreotide works like a more powerful version of a natural hormone in your body called somatostatin. Depending on what it's prescribed for, it either lowers your growth hormone levels (in acromegaly) or quiets the hormones that your tumor is releasing to cause diarrhea and flushing (in carcinoid tumors or VIPomas). Think of it as a 'volume dial' that turns down runaway hormone signals. Your doctor chose it because your condition wasn't controlled well enough with surgery, radiation, or other treatments alone.
How do I take Mycapssa correctly — does it matter if I eat first? ▾
Yes, timing around food matters a lot with Mycapssa. You need to take it on a completely empty stomach — at least one hour before you eat anything, or at least two hours after your last meal. Taking it with food can reduce how much of the medicine your body absorbs by around 90%, which means it would barely work. Swallow the capsule with a full glass of water and try to make it a consistent habit tied to a specific time in your day.
What side effects should I expect, and which ones mean I need to call my doctor? ▾
The most common side effects are digestive ones — diarrhea, stomach pain, gas, nausea, and sometimes constipation. These often ease up after the first month of treatment. What you do want to call your doctor about promptly: severe stomach or upper-right belly pain (could be your gallbladder), a very slow or irregular heartbeat, feeling shaky and sweaty (low blood sugar), or unusual fatigue and weight gain (possible thyroid issue). Don't ignore those — they're real warning signs with this medicine.
I've heard octreotide can cause gallstones. How serious is that risk? ▾
It's a real risk worth knowing about. Octreotide slows down your gallbladder, and over time that can lead to sludge or gallstones forming. In clinical studies, more than half of patients on long-term therapy developed some kind of gallbladder change. Most people don't feel anything, but some do develop painful complications. Your doctor will likely monitor your gallbladder periodically. If you get sudden severe pain in your upper right belly, especially after eating, contact your doctor right away.
Can octreotide affect my blood sugar or other lab values? ▾
Yes. Octreotide disrupts the normal balance between insulin and glucagon, so your blood sugar can go either too low or too high. Your doctor will want to monitor your glucose, especially when you're starting the medicine or changing your dose. It can also slow your thyroid over time, and some patients develop lower vitamin B12 levels. These are all manageable — but they require regular blood work, so please keep your monitoring appointments.
I'm a woman of childbearing age — is there anything I should know about octreotide and pregnancy or birth control? ▾
There are two things to know. First, if you have acromegaly, treating it with octreotide can actually improve your fertility — so if you're not trying to get pregnant, you should use reliable contraception. Second, if you take Mycapssa and use hormonal birth control pills containing levonorgestrel, octreotide may reduce how well those pills work. Talk to your doctor or pharmacist about using a backup or non-hormonal contraceptive method. If you do become pregnant, let your doctor know right away so the risks and benefits can be reassessed.
Is Octreotide available over the counter? ▾
Octreotide is dispensed by prescription according to its FDA labeling, so it isn't sold over the counter. Your prescriber and pharmacist will determine if it's appropriate for you.
When was Octreotide first available? ▾
Octreotide has been available in the United States since at least 1988, based on FDA approval history (Drugs@FDA) and product marketing records.
Who makes Octreotide? ▾
Octreotide is supplied by 33 manufacturers listed in the FDA NDC Directory, including Novartis Pharmaceuticals Corporation, Sagent Pharmaceuticals, Mylan Institutional LLC.

💬 Answers drafted from Octreotide’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →

🧰 Keep exploring

📊Octreotide supplement interactions30 checked — ranked by severity 🌿Drug & Supplement CheckerOctreotide vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Octreotide NDCs & costs 🅰️Browse Drugs A–ZLook up any medication

💊 How Octreotide comes

Octreotide is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Injection

Into a vein · Under the skin
Brands BYNFEZIA Pen Sandostatin
How this form is used
What it may be used for
  • Octreotide acetate injection and Sandostatin injection are used to reduce growth hormone and IGF-1 levels in acromegaly when surgery, radiation, or other treatments have not worked well enough
  • BYNFEZIA Pen is used to reduce growth hormone and IGF-1 levels in acromegaly
  • Octreotide acetate injection and Sandostatin are used to treat severe diarrhea and flushing episodes from metastatic carcinoid tumors
  • Octreotide acetate injection, BYNFEZIA Pen, and Sandostatin are used to treat profuse watery diarrhea caused by VIPomas
Important instructions
  • BYNFEZIA Pen is given only by subcutaneous (under-the-skin) injection; rotate injection sites among the abdomen, front of the thighs, or back of the upper arms
  • Sandostatin injection and octreotide acetate injection may be given subcutaneously or intravenously; rotate subcutaneous injection sites regularly
  • BYNFEZIA Pen should be at room temperature before injecting to reduce injection-site reactions
  • Octreotide acetate injection and Sandostatin injection are given multiple times daily as directed by your prescriber — follow the schedule exactly
Available strengths 6 strengths
50 mcg/mL 100 mcg/mL 200 mcg/mL 500 mcg/mL 1000 mcg/mL 2.5 mg/mL
91 FDA-listed product records ⓘ

Delayed-release capsule

By mouth
Brands Mycapssa
How this form is used
What it may be used for
  • Mycapssa is approved for long-term maintenance treatment of acromegaly in patients who have already responded to and tolerated octreotide or lanreotide injections
Important instructions
  • Mycapssa must be taken on an empty stomach — at least 1 hour before a meal or at least 2 hours after eating
  • Mycapssa should be swallowed with a full glass of water
  • Taking Mycapssa with food can reduce absorption by approximately 90% — do not take it with meals
  • IGF-1 levels and symptoms should be monitored every two weeks during dose adjustment, then monthly once a stable dose is reached
Available strengths 1 strength
20 mg
4 FDA-listed product records ⓘ

📊 Octreotide across the U.S. market

How Octreotide appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

2
Dose forms ⓘ
33
Manufacturers
6
Brand names
133
FDA-listed product records ⓘ
1988
First marketed ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (20) · Kit (18) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Novartis Pharmaceuticals Corporation16%
Sagent Pharmaceuticals11%
Mylan Institutional LLC11%
Fresenius Kabi USA, LLC9%
Hikma Pharmaceuticals USA Inc.8%
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.8%
Other makers38%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

📈 How widely Octreotide is used

A general measure of how commonly Octreotide is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Octreotide is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

6,900
Medicaid prescriptions filled (Q1–Q4 2025)
$24.9M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Octreotide prescribed? Of the 1,596 medications we measure, Octreotide ranks #993 by Medicaid prescriptions — more than 38% of them.

Where Octreotide ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #993 of 1,596
#988 Pegcetacoplan Injectio... 7,158 Rx #989 Somapacitan-beco Injec... 7,035 Rx #990 Fingolimod 6,946 Rx #991 Canakinumab Injection 6,924 Rx #992 Vericiguat 6,901 Rx #993 Octreotide 6,900 Rx #994 Silodosin 6,899 Rx #995 Neostigmine Methylsulf... 6,840 Rx #996 Diroximel Fumarate 6,829 Rx #997 Octreotide Injection 6,763 Rx #998 Olaparib 6,734 Rx

Utilization by Octreotide product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 30 mg injection is the most-dispensed Octreotide product — about 40% of these Medicaid prescriptions.

octreotide 30 MG Injection Most dispensed

2,732 Medicaid prescriptions (Q1–Q4 2025) 40% of Octreotide prescriptions shown $15.1M gross reimbursement (before rebates) ≈ $5,519 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 898601

octreotide 20 MG Injection

1,822 Medicaid prescriptions (Q1–Q4 2025) 26% of Octreotide prescriptions shown $7.9M gross reimbursement (before rebates) ≈ $4,326 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 898589

1 ML octreotide 0.1 MG/ML Injection

747 Medicaid prescriptions (Q1–Q4 2025) 11% of Octreotide prescriptions shown $62,624 gross reimbursement (before rebates) ≈ $84 per prescription (gross)

Summed across the 6 of 25 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 312069

octreotide 0.2 MG/ML Injectable Solution

647 Medicaid prescriptions (Q1–Q4 2025) 9% of Octreotide prescriptions shown $79,416 gross reimbursement (before rebates) ≈ $123 per prescription (gross)

Summed across the 2 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 314152

1 ML octreotide 0.5 MG/ML Injection

395 Medicaid prescriptions (Q1–Q4 2025) 6% of Octreotide prescriptions shown $148,027 gross reimbursement (before rebates) ≈ $375 per prescription (gross)

Summed across the 3 of 22 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 312070

octreotide 1 MG/ML Injectable Solution

158 Medicaid prescriptions (Q1–Q4 2025) 2% of Octreotide prescriptions shown $113,410 gross reimbursement (before rebates) ≈ $718 per prescription (gross)

Summed across the 3 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 312071

octreotide 20 MG Delayed Release Oral Capsule

137 Medicaid prescriptions (Q1–Q4 2025) 2% of Octreotide prescriptions shown $1.5M gross reimbursement (before rebates) ≈ $10,614 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2380611

1 ML octreotide 0.05 MG/ML Prefilled Syringe

135 Medicaid prescriptions (Q1–Q4 2025) 2% of Octreotide prescriptions shown $13,553 gross reimbursement (before rebates) ≈ $100 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1090559

1 ML octreotide 0.05 MG/ML Injection

72 Medicaid prescriptions (Q1–Q4 2025) 1% of Octreotide prescriptions shown $3,476 gross reimbursement (before rebates) ≈ $48 per prescription (gross)

Summed across the 2 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 312068

1 ML octreotide 0.1 MG/ML Prefilled Syringe

41 Medicaid prescriptions (Q1–Q4 2025) <1% of Octreotide prescriptions shown $13,550 gross reimbursement (before rebates) ≈ $330 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1090558

octreotide 10 MG Injection

14 Medicaid prescriptions (Q1–Q4 2025) <1% of Octreotide prescriptions shown $47,569 gross reimbursement (before rebates) ≈ $3,398 per prescription (gross)

Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 898605

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Octreotide, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 24 of 104 listed Octreotide NDCs with Medicaid activity.

🔍 Compare Octreotide products

A representative set of FDA-listed product records for Octreotide — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 133 of 133 products — FDA National Drug Code Directory. See every product, package size and price: browse all 133 Octreotide NDCs →

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Octreotide RxCUI 7617 5 dose forms · 13 strengths
  1. Dose form (SCDF) Delayed Release Oral Capsule RxCUI 2380610 In current FDA listings
    Clinical drug / strength (SCD) 20 MG RxCUI 2380611
  2. Dose form (SCDF) Injectable Solution RxCUI 373140 In current FDA listings
    Clinical drug / strength (SCD) 0.2 MG/ML RxCUI 314152 1 MG/ML RxCUI 312071
  4. Dose form (SCDF) Pen Injector RxCUI 2360542 In current FDA listings
    Clinical drug / strength (SCD) 2.8 ML octreotide 2.5 MG/ML RxCUI 2360543

Look up RxCUI 7617 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

🏷️ Sold under these brand names

Mycapssa Sandostatin Bynfezia Sandostatin LAR Depot BYNFEZIA Pen

🏭 Manufacturers & labelers

Novartis Pharmaceuticals Corporation 21 Sagent Pharmaceuticals 15 Mylan Institutional LLC 15 Fresenius Kabi USA, LLC 12 Hikma Pharmaceuticals USA Inc. 10 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 10 Gland Pharma Limited 8 Teva Parenteral Medicines, Inc. 5 Glenmark Pharmaceuticals Inc., Usa 4 Teva Pharmaceuticals, Inc. 3 Meitheal Pharmaceuticals, Inc. 3 Amryt Pharmaceuticals Designated Activity Company 2 Sun Pharmaceutical Industries, Inc. 2 Hainan Shuangcheng Pharmaceuticals Co., Ltd. 2 Bachem AG 2 Bachem Americas, Inc. 2 USV Private Limited 1 Fresenius Kabi Ipsum Srl 1 Ambiopharm, Inc. 1 Assia Chemical Industries Ltd - Teva Tech Site 1 Aurobindo Pharma Limited 1 Sterling Pharma Solutions Limited 1 Sinopep-Allsino Biopharmaceutical Co., Ltd. 1 ScinoPharm Taiwan Ltd. 1

…and 9 more on the FDA NDC directory.

RxNorm drug class

Octreotide belongs to the Somatostatin Analog class.

Pharmacologic class Somatostatin Analog
Drug family (ATC) Somatostatin and analogues
How it works Somatostatin Receptor Agonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

🔬 Where this comes from

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jul 30, 2024
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Octreotide.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Octreotide after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
14
NDC products indexed
133
Distinct labelers/manufacturers represented
33
Linked representative label ⓘ
Teva Pharmaceuticals, Inc.
Linked label effective
Jul 30, 2024
Composite sections available
24
Linked SPL Set ID
d9739ea6-74de-4a41-a806-6e827a23cedb
Linked SPL Document ID
2e77a034-b0ae-4694-8ac0-ae1319754d3a
Open the linked representative label on DailyMed ↗

How we combine label and product data

HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 14 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.

For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Teva Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.

This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.